Kornimate/medical-research-clean huggingface dataset:
comprehensive oral care long-term care facilities

Conditions: Dysphagia

Summary: oral care is a common way of caring for long-term care facility residents, particularly for those with swallowing difficulties, as oral health is closely related to eating function. oral care includes general oral hygiene and comprehensive oral care (including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing). regular oral care can reduce oral diseases, improve oral mucosa, increase appetite, and improve eating function. however, it is still unclear whether comprehensive oral care can improve eating function and aid in removing nasogastric tubes. therefore, this study plans to recruit residents with dysphagia from multiple long-term care facilities nationwide to investigate the impact of comprehensive oral care on nasogastric tube removal. the study will collect basic information, disease diagnosis, and onset time and use random grouping to investigate the effects of general oral hygiene and oral care on nasogastric tube removal. the results of this study can provide guidance for clinical practitioners and researchers on oral care and eating function improvement for long-term care facility residents.


Eligibility criteria:
inclusion criteria: * aged 18 years or older, with swallowing disorders classified as grades 1-3 on the functional oral intake scale (fois). * conscious and alert. * able to follow simple one-step commands (e.g., raising a hand, opening the mouth). * able to maintain a seated position for more than 15 minutes. * has a swallowing reflex (able to swallow saliva on command). exclusion criteria: * acute infection. * hypoxemia (sao2 \< 90%) or requiring the use of a ventilator. * structural abnormalities of the oropharyngeal area that prevent oral feeding. * failing the water swallow test (coughing or wet voice in two or more out of three attempts, or no significant laryngeal elevation).

Keywords: dysphagia oral care nasogastric tube
impact of obsidian ® asg on anastomotic healing

Conditions: Anastomotic Leak Rectum

Summary: the use of regenerative medicine in colorectal surgery constitutes an entirely new therapeutic principle. the aim of this new therapeutic approach is to reduce the anastomotic leak rate and minimise morbidity and mortality. the literature identifies the leak rate for colorectal operations as 3-39%.

introduction: the use of regenerative medicine in colorectal surgery constitutes an entirely new therapeutic principle. the aim of this new therapeutic approach is to reduce the anastomotic leak rate and minimise morbidity and mortality. the literature identifies the leak rate for colorectal operations as 3-39%. methods: this is a prospective, multi-centre descriptive study commencing in june 2018. as part of the elective laparoscopic colorectal surgery, an autologous fibrin matrix was used as part of anastomotic technique in conjunction with activated thrombocytes (obsidian asg®). during anastomosis, this matrix was applied after resection onto the colorectal tissue surfaces with the aim of triggering tissue regeneration and improved wound healing.

Eligibility criteria:
inclusion criteria: elective laparoscopic colorectal surgery with a primary anastomosis treatment exclusion criteria: 1. pregnancy 2. breastfeeding period 3. concomitant disease with the potential for a relevant impairment of the anastomosis durability (leukemia, cirrhosis of the liver, child pugh a-c)

Keywords: colorectal surgery anastomotic leak obisidan
defining an immunological signature related to lesion location in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the objective of apollo is therefore to identify biomarkers associated with the cns involvement phenotype in early ms patients.

this is a multicenter, non-interventional, retrospective cohort study. in ms patients, a recent study suggests that the location of lesions in the brain relative to the me is associated with different effector t cell responses (th17 vs. th1) to myelin proteins. thus, lesion localization may be associated with different immune profiles. recently, high-resolution techniques such as mass cytometry (cytof) have allowed to better decipher immune diversity and thus to identify new potential therapeutic targets. the combination of cytof and high dimensional analysis techniques (visne, spade, mem) offers robust and reliable methods to identify new subgroups within heterogeneous cell populations. several studies have explored immune subpopulations by these methods, including b, t, nk or myeloid populations, from peripheral blood or tissues in other pathologies. genetic analysis of regions of interest in ms patients could thus allow the establishment of stratification elements potentiating the contribution of immunological markers. the main objective is to evaluate the relevance of an immunological stratification by cytof, allowing the identification of new immune subpopulations associated with the lesion phenotype (brain or brain + me), in a cohort of ms patients at the beginning of the disease (cis+) the second objective will focus on genomic profiling of our two groups of ms patients (brain/brain + me) for different genetic burdens of ms

Eligibility criteria:
inclusion criteria: * patients with clinically isolated syndrome (cis) participating in the ofsep cohort (french ms observatory) * at least 18 years old * diagnosed with ms according to the 2017 criteria at the time of their last visit * not opposed to participating in the study * had at least one visit in the year following sampling * followed up for at least 1 year after collection. * signed ofsep consent form exclusion criteria: * cis patients with progressive ms
the effect of omega 3 supplementation on postoperative delirium in elderly patients undergoing major cardiac surgery

Conditions: Postoperative Delirium

Summary: the purpose of this study is to determine whether giving omega-3 fatty acids prior to and after cardiac bypass surgeries decreases the incidence of postoperative delirium in patients aged 65 and over.

patients aged 65 years and over requiring elective cardiac bypass surgeries will receive either 0, 2, or 4 grams of omega-3 ethyl esters before their surgery and for 3 days postoperatively to determine whether there is an affect on the incidence of postoperative delirium. all patients will receive hospital standard of care therapy for their surgery and hospital stay.

Eligibility criteria:
inclusion criteria: * age ≥ 65 years * american society of anesthesiologists (asa) class physical status i-iv exclusion criteria: * inability to obtain written informed consent. * inability to take study drug due to intubation or other reason. * delirium present at screening. * known hypersensitivity (e.g. anaphylactic reaction) to omega-3 ethyl esters or any of its components * allergy to fish or shellfish * currently taking warfarin (coumadin), apixaban (eliquis), dabigatran (pradaxa), edoxaban (savaysa/lixiana), rivaroxaban (xarelto), or other anticoagulant drugs. * currently taking omega-3, omega-6, vitamin e, or fish oil supplements. * significant renal disease with a serum creatinine ≥ 2 mg/dl. * significant liver disease with alanine aminotransferase (alt) levels 1.5 times the normal range of 6-45 units/liter and aspartate transferase (ast) levels 1.5 times the normal range of 10-42 units/liter. * history or diagnosis of diabetes. * history or diagnosis of neurodegenerative disease such as parkinson's, alzheimer's, or dementia. * history or diagnosis of bleeding disorder. * history or diagnosis of metabolic syndrome or disorder. * history or diagnosis of thyroid problems such as hyperthyroidism or hypothyroidism.

Keywords: postoperative delirium delirium fish oil omega 3 lovaza cardiac bypass omega 3 ethyl esters
safety of a second dose of biken's varicella vaccine

Conditions: Varicella

Summary: the objective of the present study is to assess and document the safety of a second dose of varicella biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of varicella biken vaccine. all subjects will receive a second dose of varicella vaccine (varicella biken) at 4 to 6 years of age. the expected total duration of follow-up (first visit to last visit) for each subject will be one month.


Eligibility criteria:
inclusion criteria : * aged 4 to 6 years on the day of inclusion. * informed consent form signed by the parent(s) or legal guardian and by an independent witness. * subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures. * written documentation of receipt of a first dose of varicella biken vaccine more than 3 months before inclusion. exclusion criteria: * participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination. * planned participation in another clinical trial during the present trial period. * known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy. * known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances. * chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator. * receipt of any vaccine in the 4 weeks preceding the trial vaccination; * planned receipt of any vaccine in the 4 weeks following the trial vaccination. * known human immunodeficiency virus (hiv), hepatitis b surface antigen, or hepatitis c seropositivity. * history of varicella infection (confirmed either clinically, serologically or microbiologically). * previous vaccination against varicella disease with a vaccine different from varicella biken vaccine. * febrile illness (temperature ≥ 37.5°c) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.

Keywords: varicella-zoster virus varicella
prospective cohort study of traditional chinese medicine for survival of patients with early breast cancer

Conditions: Early-stage Breast Cancer

Summary: this 2-year trial is intended to be used to study breast cancer patients through forward-looking generation design through collaboration between chinese and western medical teams. the whole study consists of 2 stages, stage i comprises a cross-sectional study-baseline and stage ii is a cohort for outcome evaluation and follow-up study across a 3-year period. to provide an empirical basis for combined tcm treatment in the breast cancer research team and to publish that as a reference for future tcm and western medicine in integrative cancer treatment.

breast cancer is a major health issue for women worldwide and has increased exponentially in the last decades. improved earlier detection combined with adjuvant systemic therapy is responsible for much of the reduction in cause-specific mortality from breast cancer. chemotherapy after surgery can decrease the risk of recurrence and is often used as routine treatment in clinic. because of the fact that a considerable number of patients seek for traditional chinese medicine (tcm) during adjuvant chemotherapy, it is thus need to evaluate the correlation between tcm treatment and prognosis. the investigators design a single center, prospective cohort study began in november 2018 in kaohsiung, taiwan. a sample of 104 participants diagnosed with early breast cancer was recruited from breast cancer research team and are followed up every 3 to 6 months till october 2023. detailed information of participants includes general information, history of cancer, quality of life, side effects of chemotherapy and safety of treatment, body constitution of tcm and meridian energy analysis is taken face-to-face at baseline.

Eligibility criteria:
inclusion criteria: * aged \> 20 years old female patients; * patients with histologically proven stage 1-3 breast cancer after surgery; * the duration from the end of radical surgery to the beginning of the trail is less than 1 month; * ecog score is 0-2 points; * agreed to participate in this study and signed informed consent. exclusion criteria: * combined with inadequate heart, liver, kidney and hematopoietic function and other serious diseases; * pregnant and lactating women; * patients with a history of mental illness; * patients with distant metastasis and/or expected lifetime less than 3 months; * patients undergoing other medicinal herbs outside our hospital.

Keywords: traditional chinese medicine quality of life disease-free survival adjuvant chemotherapy breast cancer
neuromotor control during walking in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: one out of every three children with cerebral palsy (cp) falls daily, with more than half of the falls occurring while walking. to avoid falling, the nervous system must continuously monitor how the body moves and, when an imbalance is detected, activate muscles for an appropriate correction. in this project, we will use small electrical stimulation of muscles and tendons that enhances the sense of body positioning, to allow children with cp to generate more accurate balance corrections.


Eligibility criteria:
inclusion criteria: * age 8 - 24 years * diagnosis of spastic diplegic or hemiplegic cp (for participants with cp group only) * gmfcs classification level i or ii (ability to walk independently with using any assistive device) * visual, perceptual, and cognitive/ communication skills to follow multiple step commands * seizure-free or well controlled seizures * ability to communicate pain or discomfort during testing procedures * parental/guardian consent and child assent/consent exclusion criteria: * diagnosis of athetoid, ataxic or quadriplegic cp * significant scoliosis (scoliometer angle \> 9°) * history of selective dorsal root rhizotomy * botox injections in the lower limb within the past 6 months * severe spasticity of the lower extremity muscles (e.g. a score of 4 on the modified ashworth scale) * severely limited range of motion/ irreversible muscle contractures * lower extremity surgery or fractures in the year prior testing * joint instability or dislocation in the lower extremities * marked visual or hearing deficits

Keywords: locomotor control balance
predicting cardiometabolic risk in mild-to-moderate obstructive sleep apnea: inflammation vs. apnea/hypopnea index

Conditions: Obstructive Sleep Apnea

Summary: the purpose of the study is to compare the relative contribution of systemic inflammation vs. obstructive sleep apnea (osa) severity (as measured by apnea hypopnea index) in predicting cardiovascular and metabolic aberrations associated with mild-to-moderate obstructive sleep apnea.


Eligibility criteria:
inclusion criteria: * mild to moderate osa (5≤ ahi \<30) * bmi ≤ 45 * age ≥ 18 * men \& women exclusion criteria: * ahi ≥ 30 * bmi \>45 * current use of steroids or anti-inflammatory medication * diagnosis of insulin dependent diabetes * diagnosis of autoimmune disorder * shiftwork * current use of cpap
exercise perceptions and preferences among rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to analyse exercise behaviour of rheumatoid arthritis patients.


Eligibility criteria:
inclusion criteria: * rheumatoid arthritis * age 30 to 80 years exclusion criteria: * language difficulties and no help from family members or friends

Keywords: exercise barriers benefits preferences stages of change
the effect of proprioceptive neuromuscular facilitation techniqueson in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the aim of this study is to examine the effects of pnf techniques on pain, motor function, fatigue and quality of life.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of relapsing-remitting ms (rrms) as defined by mcdonald criteria * 18-65 years of age * an expanded disability status scale (edss) score \< 4 * relapse-free for the last 3 months * cognitive impairment that was defined with mini mental test. exclusion criteria: * a history of different neurological diseases * having any contraindication for exercise * having orthopedic, vision, hearing, or perception problems.

Keywords: multiple sclerosis proprioceptive neuromuscular facilitation pain motor function fatigue quality of life
observational study on patients with hepatobiliary tumors

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gallbladder Cancer; Biliary Tract Cancer; Gastric Cancer; Colorectal Cancer

Summary: hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans. in recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, however, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. in this study, we collected a wide rang of patients' information, including photos of patients' face, physical strength and nutrition indicators, blood ,stool and pathological tissue specimens from tumor patients, then multi-omics testing were applied to looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.

this is an ongoing, longitudinal, observational clinical cohort study of patients with tumors of the alimentary tract, mainly hepatobiliary tumors. all the patients are diagnosed, treated and followed up. in the future, some other patient information will be gradually updated to this database

Eligibility criteria:
inclusion criteria: 1. be older than 18 years old; 2. clinical or pathological diagnosis of malignant hepatobiliary tumors; 3. patients have received or are about to receive surgery, chemotherapy radiotherapy, targeted therapy, local therapy, immunotherapy, etc; 4. patients understand and are willing to sign written informed consent. exclusion criteria: 1. patients considered by the doctor to be unsuitable for entry into this study (mental disorder or poor compliance, etc.); 2. the patient or guardian is unwilling to participate in this study; 3. pregnant women; 4. combined with other serious systemic diseases (heart failure, renal failure,hematopoietic system disease or uncontrollable acute infection); 5. estimated survival time is less than 1 month.

Keywords: hepatocellular carcinoma cholangiocarcinoma gallbladder cancer biliary tract cancer blood sample tissue sample stool sample
non-invasive measurements of changes in pulmonary artery pressure in intensive care unit patients using electrical impedance tomography - a feasibility study

Conditions: Pulmonary Artery Hypertension

Summary: to assess whether changes in electrical impedance - measured using an electrical impedance tomography (eit) chest belt - can be used to derive changes in pulmonary artery pressure (pap) in critically ill patients when compared to invasive gold-standard pap measured using pulmonary artery catheter (pac).


Eligibility criteria:
inclusion criteria: * age ≥ 18-year-old. * intubated patients in the icu with clinical decision to monitor pap and cardiac output using a pac. exclusion criteria: * patients with implanted or external thoracic electronic devices (e.g., pacemaker) or thoracic metal implants. * known pregnancy or lactating patients. * open lung injuries or pneumothorax. * open wounds, drainages, burns or rashes of the upper thorax. * estimated thoracic perimeter smaller than 66 cm or larger than 134 cm. * known allergies to wound dressings or adhesives (e.g., gel electrodes)
study of eyp-1901 in subjects with wet age related macular degeneration (wamd)

Conditions: Wet Age-related Macular Degeneration

Summary: this is a phase 2 randomized, double -masked study comparing the efficacy of eyp-1901 at two dose levels: 2060 ug and 3090 ug against aflibercept.

this study is evaluating the two doses of 1901 against aflibercept in a randomized study.

Eligibility criteria:
inclusion criteria: * documented diagnosis of wamd in the study eye, with disease onset any time prior to the screening visit. * previously treated with at least two anti vegf intravitreal injections (i.e., bevacizumab, ranibizumab, aflibercept or faricimab) for wamd per standard of care in the study eye within 6 months prior to the screening visit. * bcva etdrs letter score of 35 letters (20/200 snellen equivalent) to 85 letters (20/20 snellen equivalent) in the study eye at the screening visit and on day 1. exclusion criteria: * central subfield thickness (cst) \> 350 µm in the study eye at the screening visit or day 1. * any concurrent intraocular condition in the study eye (e.g., cataract or glaucoma). * historical or active intraocular inflammation (grade trace or above) in the study eye, other than expected findings from routine cataract surgery.

Keywords: wamd eyp-1901 eyepoint
the impact of 8 weeks of a digital meditation application on work stress

Conditions: Stress; Psychological; Behavioral Symptoms

Summary: the aim of this study is to test the effects of a digital meditation intervention in a sample university of california, irvine (uci) employees who report mild to moderate stress. uci employees will be randomized to either 8-weeks of a digital meditation intervention (using the commercially available application headspace) or a waitlist control condition.

the aim of this study is to test the effects of a digital meditation intervention in a sample uci employees who report moderate to high stress. uci employees will be randomized to either 8-weeks of a digital meditation intervention (using the commercially available application headspace) or a waitlist control condition. participants assigned to the intervention group will be asked to download and use the headspace mobile application for at least 10 minutes per day for 8 weeks. all study participants will be asked to fill out short (no longer than 25 minutes) questionnaires at baseline, week 4, week 8 (post intervention), and a 4-month follow up period. among participants who are randomized to the digital meditation intervention, they will also take part in a 1-year follow up. all activities will take place online (via computer or smartphone). prior to randomization, participants will go through an eligibility screening and complete the baseline questionnaire battery. the entirety of the study is digital and there are no in-person assessments. adherence will be tracked remotely. the goal is to recruit as many as 2000 participants (1000 per condition).

Eligibility criteria:
inclusion criteria: you may join if you: * have access to a smartphone or computer every day * are fluent in english * are a ucsf employee * report mild to moderate levels of stress * consent: demonstrate understanding of the study and willingness to participate as evidenced by voluntary informed consent and has received a signed and dated copy of the informed consent * are at least 18 years of age exclusion criteria: * you may not join if you are an experienced meditator or have participated in a formal meditation practice in the last 6 months (defined as once or more per week for a duration of 20 minutes or more at each practice)

Keywords: stress mindfulness work related stress health meditation